serine/threonine protein kinase; interleukin 6; interleukin 8; growthrelated oncogene-␣ THE CENTRAL ROLES of vascular endothelial growth factor (VEGF, also termed VEGF-A) and the bioactive VEGF receptor 2 (VEGFR2, also termed Flk-1 or KDR) in vascular development during embryogenesis and angiogenesis in the adult have been well documented (24) . However, emerging evidence indicates that VEGF also plays a critical role in host inflammatory responses in several disease states, including atherosclerosis, sepsis, and rheumatoid arthritis. It has been recently shown that DNA vaccination against VEGFR2 reduces atherosclerosis in low-density lipoprotein receptor-or apolipoprotein E (apoE)-deficient mice (12, 25) . These findings indicate that VEGFR2 activity plays an important role in the development of atherosclerosis, a chronic inflammatory disease of the vessel wall. Moreover, VEGF delivery induces the progression of atherosclerotic plaque by promoting leukocyte recruitment and neovascularization in cholesterol-fed rabbits and in apoE-or apoE/apoB100-deficient mice (6, 7, 18, 21) , although a disparate result has been reported (19) . VEGF is absent in healthy human arteries but is strongly expressed in early and advanced atherosclerotic lesions, and the degree of its expression increases with severity of atherosclerosis (14, 22) . Conversely, VEGF blockade inhibits early vascular inflammation, neointimal formation, and atherosclerosis by suppressing monocyte recruitment and intraplaque angiogenesis (23, 38 -40) . Besides atherosclerosis, it has been recently reported that VEGF is an important determinant of sepsis morbidity and mortality (37) . Additionally, VEGF is also functionally involved in host inflammatory responses in acute lung injury (15, 35) , rheumatoid arthritis (9, 11) , and inflammatory bowel disease (33) . These studies indicate that VEGF possesses proinflammatory and proatherosclerotic properties; however, the signal pathways responsible for VEGF's proinflammatory activity are currently not clear.
Protein kinase D1 (PKD1, also known as PKC-) is the founding member of a newly described serine/threonine protein kinase family that includes PKD2 and PKD3 (PKC-) (27) . PKD contains a tandem repeat of zinc finger-like cysteine-rich motifs at its NH 2 terminus that display high affinity for diacylglycerol or phorbol ester, a pleckstrin homology domain, and a COOH-terminal catalytic domain that shares homology with the calmodulin-dependent kinases (27) . Although PKD family kinases exhibit a homologous catalytic domain, they vary with respect to their subcellular localization, expression, and regulation (1, 26, 27) . PKD1 has been implicated to be functionally involved in cell migration, survival/ apoptosis, and membrane trafficking (27) ; however, it is not known whether it regulates vascular inflammatory responses. Furthermore, relatively few in vivo PKD1 targeting genes have been identified so far. In addition, little is known about the biological functions of PKD2 and PKD3.
In this study, we report that VEGF, via VEGFR2-PKD1 axis, predominantly induces the production of proinflammatory cytokine interleukin (IL)-6 and CXC chemokines IL-8 and growth-related oncogene-␣ (GRO-␣) in endothelial cells (ECs) but not in leukocytes, which may be an important event mediating the proinflammatory activity of VEGF.
Cruz, CA). PKD2 and PKD3 antibodies were from Upstate (Lake Placid, NY) and Bethyl Laboratories (Montgomery, TX), respectively.
Cell culture and treatment. Primary human aortic ECs (HAECs) and human umbilical vein ECs (HUVECs) were from Lonza (Walkersville, MD) and were cultured in endothelial growth medium (EGM)-2 and used for experiments within eight passages. ECs were normally starved 1.5 h in serum-free endothelial basal medium before treatment. Human peripheral blood mononuclear cells were isolated from heparinized blood samples drawn from healthy volunteers, using procedures approved by the Institutional Review Board of University of Texas Health Science Center at Tyler.
Cytokine antibody array and enzyme-linked immunosorbent assay. Cytokine antibody array was performed with a human cytokine array kit (R&D Systems) according to the manufacturer's protocol. IL-6 and IL-8 in cell culture supernatants were measured with DuoSet ELISA development kits (R&D Systems) following the manufacturer's protocols.
RNA isolation and RT-PCR. Total RNA was isolated, and semiquantitative RT-PCR was performed according to the manufacturer's protocol (Qiagen, Valencia, CA) using the following primers: IL-6 (expected product of 481 bp), 5Ј-ACA TCC TCG ACG GCA TCT CAG-3Ј (forward) and 5Ј-AAT CTG AGG TGC CCA TGC TAC-3Ј (reverse); IL-8 (343 bp), 5Ј-TTT GCC AAG GAG TGC TAA AGA-3Ј (forward) and 5Ј-GCA TCT GGC AAC CCT ACA ACA-3Ј (reverse); GRO-␣ (516 bp), 5Ј-GCC CAA ACC GAA GTC ATA GCC-3Ј (forward) and 5Ј-ATC CGC CAG CCT CTA TCA CA-3Ј (reverse); and internal control GAPDH, 5Ј-CGC TGA GTA CGT CGT GGA G-3Ј(forward) and 5Ј-GAG GAG TGG GTG TCG CTG TTG-3Ј (reverse). RT-PCR conditions were 50°C for 30 min and 95°C for 15 min, followed by 30 cycles of 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min, followed by 72°C for 10 min. Relative change in mRNA was measured by densitometric analysis and normalized to GAPDH.
Western blot analysis. Western blot analysis was performed essentially as we described previously (34) .
Small interference RNA and small interference RNA transfection. AllStars nontargeting negative control small interference RNA (siRNA) (no. 1027280) and the validated human VEGFR2 (no. SI00605528), PKD1 siRNA-1 (PKD1-S1, no. SI00301350), PKD1 siRNA-2 (PKD1-S2, no. SI00042378), PKD2 siRNA (no. SI02224768), and PKD3 siRNA (no. SI02223977) were from Qiagen. The ONTARGETplus SMARTpool duplexes of predesigned human PKD1 siRNA-3 (PKD1-S3, no. 005028) were from Dharmacon (Chicago, IL). For siRNA transfection, HUVECs were seeded into different plates for 24 h to reach 50 -70% confluence, and siRNA was then transfected into HUVECs in a final concentration of 20 nM by using Lipofectamine 2000 and Opti-MEM reduced serum medium according to the manufacturer's protocols (Invitrogen, Carlsbad, CA). The medium was replaced with fresh EGM-2 medium 12 h after transfection. The silencing effects of siRNAs were then confirmed by Western blot analysis.
Statistical analysis. Data are expressed as means Ϯ SE. Student's t-test was used for statistical analysis. P Ͻ 0.05 was considered statistically significant.
RESULTS

VEGF predominantly induces the production of IL-6, IL-8, and GRO-␣ in ECs.
To identify the inflammatory cytokines induced by VEGF in ECs, we performed a human cytokine antibody array containing 36 cytokine capture antibodies immobilized on membrane as shown in Fig. 1A . The membranes were blocked and incubated with cell culture supernatants from control and VEGF-treated HAECs and a cocktail of detection antibodies. The cytokine/detection antibody complexes were then bound by their cognate immobilized capture antibodies on the membrane and visualized by chemiluminescence reagent. Interestingly, among 36 cytokines on the array, only the protein levels of GRO-␣ (no. 1), IL-6 (no. 2), and IL-8 (no. 3) were markedly increased by VEGF treatment, whereas macrophage migration inhibitory factor (MIF) and plasminogen activator inhibitor-1 (PAI-1) were slightly increased by VEGF (Fig. 1 , B and C). In contrast, we found that most cytokine array signals were not significantly affected by VEGF treatment in human peripheral blood mononuclear cells (supplemental ogy website). These data indicate that VEGF predominantly induces the production of IL-6, IL-8, and GRO-␣ in ECs but not in leukocytes.
To determine whether VEGF induces mRNAs of these three inflammatory cytokines in ECs, we performed semiquantitative RT-PCR. We found that the mRNA levels of IL-6, IL-8, and GRO-␣ were markedly increased by VEGF (25 ng/ml) in a time-dependent manner, with a maximal induction at 30 min ( Fig. 2A) . As a control, GAPDH mRNA level was not significantly affected by VEGF. In addition, MIF mRNA was also not significantly altered by VEGF (data not shown). These findings demonstrate that VEGF rapidly and markedly induces the expression of IL-6, IL-8, and GRO-␣ in ECs.
We next performed individual cytokine ELISA to characterize the kinetics and magnitude of IL-6 and IL-8 production by VEGF in ECs. We found that IL-6 and IL-8 were readily detected in both HAEC and HUVEC culture media after 1 h VEGF treatment and that their levels continued to increase , then incubated in the absence (control) or presence of VEGF165 (25 ng/ml) for 1 h. IL-6 and IL-8 released into serum-free medium were measured by ELISA and are presented as pg/ml from 1 ϫ 10 6 cells/ml. All data are means Ϯ SE (n ϭ 4). *P Ͻ 0.05 or **P Ͻ 0.01 vs. control or DMSO-treated cells. VEGFR2 and actin protein levels were assessed by Western blotting, and IL-6 in the medium was measured by ELISA and is presented as pg/ml from 1 ϫ 10 6 cells/ml. Data are means Ϯ SE (n ϭ 4). **P Ͻ 0.01 vs. control cells treated with VEGF. through 8 h (Fig. 2, B and C) . Since HUVECs grow much faster than HAECs, we used HUVECs for all the following experiments. As shown in Fig. 2, D and E, basal and the VEGF-induced production of IL-6 and IL-8 was virtually abolished by the transcription inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide. These findings indicate that the VEGF-induced production of IL-6 and IL-8 requires de novo transcription and translation. In addition, we found that VEGF was unable to induce the production of IL-6, IL-8, and MIF in human peripheral blood mononuclear cells and human MonoMac6 cells (supplemental Fig. I ). Taken together, these data demonstrate that VEGF predominantly induces the production of inflammatory cytokine IL-6 and CXC chemokines IL-8 and GRO-␣ through the upregulation of these early responsive genes to VEGF in ECs.
Comparison of cytokine and VCAM-1 induction by VEGF with other inflammatory mediators in ECs. We compared the effect of VEGF on endothelial production of IL-6 and IL-8 with other inflammatory mediators. As shown in Fig. 3, A and B, VEGF and TNF-␣ induced a comparable amount of IL-6 and IL-8 production after 4 h treatment of ECs. It should be noted that TNF-␣ at this dose strongly induced VCAM-1 expression in HUVECs, whereas, in agreement with a previous report (29) , VEGF had only a very minor effect on VCAM-1 induction (Fig. 3C ). These data suggest that IL-6 and IL-8 production by VEGF may be an important event mediating the proinflammatory activity of VEGF. In contrast, the levels of IL-6 and IL-8 in the media were not significantly altered by interferon-␥, angiotensin II, or glucose (Fig. 3, A and B) .
VEGFR2 mediates the cytokine production by VEGF in ECs. ECs express both VEGFR1 and VEGFR2. We determined the involvement of VEGF receptor subtypes responsible for the cytokine production in ECs. As shown in Fig. 4A , knockdown of VEGFR2 by 88% with a validated human VEGFR2 siRNA profoundly inhibited IL-6 production by VEGF. Moreover, SU-1498 (30), a specific inhibitor of VEGFR2 tyrosine kinase, almost completely inhibited IL-6 production by VEGF in the cells (Fig. 4B) . In addition, the VEGF-induced IL-8 production was also markedly inhibited by VEGFR2 siRNA and VEGFR2 inhibitor SU-1498 (data not shown). These results demonstrate that VEGFR2 mediates the cytokine production by VEGF in ECs. , and GRO-␣ (C) in medium were measured by ELISA and are presented as pg/ml from 1 ϫ 10 6 cells/ml. Data are means Ϯ SE (n ϭ 4). **P Ͻ 0.01 vs. control cells treated with VEGF. Fig. 6 . PKD1 plays a critical role in IL-6 induction by VEGF in ECs. HUVECs were transfected with 20 nM nontargeting control siRNA (Con. siRNA), human PKD1 siRNA-1 (PKD1-S1), PKD1 siRNA-2 (PKD1-S2), or PKD1 siRNA-3 (PKD1-S3) and grown for 72 h, then stimulated with VEGF165 (25 ng/ml) for 2 h (A-C) or 30 min (D). A: protein levels of PKD1, PKD2, VEGFR2, and actin in above transfected HUVECs were assessed by Western blotting with specific antibodies as indicated, and the mean knockdown level (%) of each protein is shown (n ϭ 4). IL-6 (B) and von Willebrand factor (vWF) (C) released into medium were measured by ELISA and are presented as pg/ml or mU/ml from 1 ϫ 10 6 cells/ml (n ϭ 4). D: IL-6 mRNA level is shown in a representative RT-PCR (n ϭ 3). Relative change in IL-6 mRNA was measured by densitometric analysis, normalized to GAPDH, and is presented as fold over control siRNA without VEGF treatment. **P Ͻ 0.01 vs. the effect of VEGF in cells transfected with control siRNA.
PKD1 plays a critical role in the VEGF-induced cytokine production in ECs.
Gö-6976 is a selective inhibitor of PKD and classical protein kinase C (PKC) isoforms (10) . As shown in Fig. 5A , the VEGF-induced IL-6 production was almost completely inhibited by Gö-6976 in HUVECs. In contrast, IL-6 induction by VEGF was not significantly affected by U-0126 (5 M), wortmannin (500 nM), or c-Jun NH 2 -terminal kinase inhibitor VIII (5 M) that selectively inhibit MAP kinase kinase-1/2, phosphatidylinositol 3-kinase, or c-Jun NH 2 -terminal kinase, respectively. Moreover, the production of IL-8 and GRO-␣ by VEGF was also abolished by Gö-6976 in HUVECs (Fig. 5, B and C) . These findings indicate that the Gö-6976-sensitive PKD and/or classical PKC members are involved in the cytokine induction by VEGF in ECs.
PKD family kinases are downstream effectors of PKC and are normally activated by a novel PKC isoform-mediated phosphorylation of two key serine residues in the activation loop, such as Ser744/748 of mouse PKD1 (27) . PKD1 is the founding member of PKD family kinases that includes PKD2 and PKD3 (27) , and the activation of PKD1 by VEGF has been reported in HUVECs and bovine aortic ECs (8, 36) . To determine the role of PKD1 in cytokine induction by VEGF, we used the loss-of-function approach by silencing PKD1 with specific siRNA duplexes that target different PKD1 mRNA regions and determined the effects on the VEGF-induced cytokine production in HUVECs. As shown in Fig. 6A (top) , PKD1 (115 kDa) and PKD2 (105 kDa) were detected in Western blots of HUVEC extracts using a PKD1/2 (C-20) antibody that recognizes both PKD1 and PKD2 (31) . Transfection of HUVECs with three different PKD1 siRNAs specifically silenced PKD1 without altering the expression levels of PKD2 and VEGFR2 (Fig. 6A) . Importantly, we found that IL-6 production by VEGF was inhibited 60% to 70% by PKD1 knockdown with three different PKD1 siRNAs (Fig. 6B) . In contrast, knockdown of PKD1 generally did not affect the release of von Willebrand factor (vWF) by VEGF (Fig. 6C) . Since vWF release by VEGF is mediated via regulated exocytosis (vesicle trafficking) of Weibel-Palade bodies that store the preformed vWF (20) , this finding suggests that PKD1 regulates IL-6 production by VEGF through an exocytosis-independent mechanism. As shown in Fig. 6D , we found that VEGF treatment increased IL-6 mRNA level and that the stimulatory effect of VEGF on IL-6 mRNA was markedly inhibited by PKD1 silencing. These data indicate that PKD1 regulates IL-6 induction by VEGF through the modulation of IL-6 mRNA level in ECs. In addition to IL-6, the VEGF-induced increased production of IL-8 and GRO-␣ was also inhibited 40% and 37% by PKD1 knockdown, respectively (Fig. 7) . These results indicate that PKD1 plays a critical role in the cytokine induction by VEGF in ECs.
Since PKD1 preferentially regulates IL-6 induction by VEGF and partially modulates the production of IL-8 and GRO-␣ in ECs, we then used the loss-of-function approach to determine the roles of PKD2 and PKD3 in the VEGF-induced cytokine production. Interestingly, we found that PKD2 silencing markedly reduced VEGFR2 expression (Fig. 8A ) and inhibited the production of IL-6 and IL-8 by VEGF in HUVECs (Fig. 8, B and C) . Similar inhibitory effects were observed in HUVECs transfected with another PKD2 siRNA (data not shown). In contrast, knockdown of PKD3 had only a minor effect on VEGFR2 protein level and the production of IL-6 and IL-8 by VEGF in ECs (Fig. 8) . These results indicate Fig. 7 . PKD1 also regulates the production of IL-8 and GRO-␣ by VEGF in ECs. HUVECs were transfected with nontargeting control siRNA or human PKD1 siRNA-1 and grown for 72 h, then either left unstimulated (control) or stimulated with VEGF165 (25 ng/ml) for 2 h. IL-8 (A) and GRO-␣ (B) released into medium were measured by ELISA and are presented as pg/ml from 1 ϫ 10 6 cells/ml. Data are means Ϯ SE (n ϭ 4). *P Ͻ 0.05 vs. control siRNAtransfected cells treated with VEGF. that PKD2 is required for EC expression of VEGFR2, thus modulating the VEGF-induced cytokine production in ECs.
DISCUSSION
Emerging evidence indicates that VEGF plays a critical role in host inflammatory responses in several disease states, including atherosclerosis (7, 12, 18, 21, 23, 25, 39, 40) , sepsis (37) , acute lung injury (15) , and rheumatoid arthritis (11) . These data indicate that besides the proangiogenic activity, VEGF has a potent proinflammatory property, although the underlying mechanism is largely unclear. In the present study, we have reported a novel finding that VEGF via VEGFR2-PKD1 axis predominantly induces the production of proinflammatory cytokine IL-6 and CXC chemokines IL-8 and GRO-␣ in ECs but not in leukocytes. We further show that the production of these inflammatory cytokines by VEGF is much stronger than the induction of adhesion molecule VCAM-1 in ECs. Because increased levels of IL-6, IL-8, and GRO-␣ produced locally or systemically are critically involved in vessel wall inflammation, our findings may provide new insights into the mechanism of the proinflammatory and proatherosclerotic activities of VEGF.
By using a cytokine antibody array that detects the end point protein products released from cells, we found that VEGF predominantly induced the production of proinflammatory cytokines IL-6, IL-8, and GRO-␣ among 36 cytokines in the array in primary human ECs but not in leukocytes. Besides IL-8 (17), the VEGF-induced production of IL-6 and GRO-␣ in ECs has not been reported to date, as far as we know. The induction of IL-6, IL-8, and GRO-␣ mRNAs by VEGF was rapid and reached a maximal level at 30 min, indicating that they are early responsive genes to VEGF. The VEGF-induced production of IL-6 and IL-8 was abolished by the transcription inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide, further demonstrating that the induction of these cytokines by VEGF requires de novo transcription and translation. IL-6 is a multifunctional cytokine that regulates immune response, inflammation, haematopoiesis, and acute phase response (16) and has been recognized as an important circulating inflammatory biomarker, predicting the risk of future cardiovascular events (2) . IL-6 is detected in atherosclerotic lesions, and elevated levels of IL-6 produced locally or systemically promote atherosclerosis (13, 28, 32) . IL-8 and GRO-␣ are initially recognized as chemoattractants of neutrophils and T-lymphocytes. However, recent studies have demonstrated that IL-8 and GRO-␣ promote the accumulation of macrophages in atherosclerotic lesions (3, 4) . Moreover, besides their leukocyte chemotactic activities, IL-8 and KC/ GRO-␣ also possess proangiogenic properties (5) . In addition to the enhanced production and release of proinflammatory cytokines and chemokines from ECs, upregulation of endothelial adhesion molecules has also been recognized to be an important regulator for endothelium activation in inflammation. We found that the VEGF-induced production of IL-6 and IL-8 was comparable to that of TNF-␣ in ECs. However, in agreement with a previous report (29) , the effect of VEGF on VCAM-1 expression was extremely small compared with that of TNF-␣. These data suggest that the strong induction of IL-6, IL-8, and GRO-␣ by VEGF in ECs may be an important event mediating the proinflammatory and proatherosclerotic activities of VEGF.
Another interesting finding from the present study is that the VEGF-induced cytokine production is essentially mediated by VEGFR2-PKD1 axis. We found that the induction of IL-6 and IL-8 by VEGF was abolished by VEGFR2 knockdown with a validated siRNA and the specific VEGFR2 inhibitor SU-1498 (30) , demonstrating that VEGFR2 mediates the VEGF-induced cytokine production in ECs. Pharmacological study revealed that the Gö-6976-sensitive PKD and/or classical PKC members are essential for the cytokine induction by VEGF in ECs. PKD family kinases are newly described serine/threonine kinases, downstream of PKC, and are normally activated by a novel PKC isoform-mediated phosphorylation of two key serine residues in the activation loop, such as Ser744/748 of mouse PKD1 (27) . PKD1 is the founding member of PKD family kinases that includes PKD2 and PKD3 (27) , and the activation of PKD1 by VEGF has been reported in ECs (8, 36) . By using siRNA technique, we clearly showed that PKD1 knockdown with three different PKD1 siRNAs markedly inhibited (ϳ70% inhibition) the induction of IL-6 by VEGF in HUVECs without affecting VEGFR2 expression. Moreover, we found that knockdown of PKD2 but not PKD3 also markedly inhibited IL-6 production by VEGF in ECs. This appears to have resulted from the downregulation of VEGFR2 by PKD2 silencing. Thus, our findings indicate that PKD1 and PKD2 regulate IL-6 induction by VEGF through two apparently different mechanisms. It appears that PKD1 is a critical signaling effector linking VEGF-VEGFR2 signal to IL-6 expression in ECs, whereas PKD2 is required for VEGFR2 expression, thus modulating the VEGF-induced cytokine production in ECs. In addition, our studies indicate that PKD1 also regulates the induction of CXC chemokines IL-8 and GRO-␣ by VEGF in ECs. However, knockdown of PKD1 only partially inhibited (ϳ40% inhibition) the induction of IL-8 and GRO-␣ by VEGF. These results suggest that the Gö-6976-sensitive classical PKC members may also play a role in the induction of IL-8 and GRO-␣ bypass PKD1 since the induction of these cytokines by VEGF was almost completely inhibited by Gö-6976, which is a selective inhibitor of PKD and classical PKC isoforms (10) .
In summary, we have obtained substantial evidence indicating that VEGF via VEGFR2-PKD1 axis induces the production of IL-6, IL-8, and GRO-␣ in ECs but not in leukocytes, which may offer new insights into the mechanism of the proinflammatory and proatherosclerotic activities of VEGF.
